🔎 Trials Near Me

Home › Breast Cancer › Connecticut

Breast Cancer clinical trials in Connecticut

46 studies for Breast Cancer are looking for participants at sites in Connecticut.

Cities in Connecticut

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Yale Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  • Yale University School of Medicine - Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07701941

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Yale University School of Medicine, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  • Yale University - Yale University School of Medicine, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07360314

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  • Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07578571

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

  • Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222267

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Yale Cancer Center ( Site 0060), New Haven
  • Stamford Hospital ( Site 0049), Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • Smilow Cancer Hospital Care Center - Derby, Derby
  • Smilow Cancer Hospital Care Center - Fairfield, Fairfield
  • Smilow Cancer Hospital at Glastonbury, Glastonbury
  • and 10 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06377852

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

  • Kivu Trial Site, New Have
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Hartford Healthcare Institute, Hartford
  • Yale Cancer Center, New Haven
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07214532

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  • Yale University School Of Medicine, New Haven
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 21, 2026 · NCT07524855

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

  • Norwalk Hospital, Norwalk
RecruitingPhase 2
Ages 45 and older · Women · Updated Sep 21, 2026 · NCT04084730

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • Yale Cancer Center Clinical Trials Office, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Yale New Haven Hospital- Yale Cancer Center, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Yale-New Haven Hospital-Yale Cancer Center, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Hartford HealthCare - Avon, Avon
  • Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
  • Danbury Hospital, Danbury
  • and 19 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • Smilow Cancer Hospital at Yale New Haven, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07029399

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

  • Yale University Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06533826

Optimizing Surgical Decisions in Young Adults With Breast Cancer

  • Yale Cancer Center, New Haven
Recruiting
Ages 18 to 44 · Women · Updated Aug 19, 2026 · NCT06275126

ATEMPT 2.0: Adjuvant T-DM1 vs TH

  • Smilow Cancer Hospital Care center at Derby, Derby
  • Smilow Cancer Hospital Care center at Fairfield, Fairfield
  • Smilow Cancer Hospital Care center at Glastonbury, Glastonbury
  • and 11 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04893109

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

  • Yale Cancer Center - Smilow Cancer Hospital, New Haven
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916

E-Mindfulness Approaches for Living After Breast Cancer

  • Stamford Hospital/Bennett Cancer Center, Stamford
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Aug 4, 2026 · NCT06748222

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Norwalk Hospital, Norwalk
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

  • Yale University, New Haven
RecruitingPhase 3
Ages 65 and older · Women · Updated Jun 30, 2026 · NCT06507618

Integrated Cancer Repository for Cancer Research

  • Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • Yale University, Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

  • Yale Cancer Center Smilow Cancer Hospital, New Haven
RecruitingPhase 1
Ages 18 and older · Women · Updated May 22, 2026 · NCT05989347

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

  • Yale Cancer Center, New Haven
RecruitingObservational study
Ages 18 to 80 · Women · Updated May 22, 2026 · NCT06551220

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  • Smilow Cancer Hospital - Derby, Derby
  • Smilow Cancer Hospital - Fairfield, Fairfield
  • Smilow Cancer Hospital - Glastonbury, Glastonbury
  • and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07062965

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  • Yale Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

  • Stamford Hospital, Stamford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • Smilow Cancer Hospital-Derby Care Center, Derby
  • Smilow Cancer Hospital Care Center-Fairfield, Fairfield
  • Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
  • and 13 more
RecruitingPhase 3
Ages 50 to 70 · All sexes · Updated Apr 23, 2026 · NCT04852887

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Yale University, Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

  • Hartford Healthcare, Hartford
  • WCHN Norwalk Hospital - Data Collection, Norwalk
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.